NCT07396792Not yet recruiting
Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram
Screening for Cardiac and Cardiac-associated Pathology Using Single-channel Electrocardiogram Analyzed With Machine Learning Models
Source: ClinicalTrials.gov · Last updated 16 Apr 2026
Brief summary (registry, in English)
It is a prospective, controlled, single-center, observational, non-randomized study. The study is planned to include at least 4000 patients 18 years old and older in the training sample and 1000 patients over 18 years old in the test sample (the total number of patients is at least 5000 people). Patients will be included in the study if they have undergone a full examination (laboratory, clinical and instrumental), allowing for the verification or exclusion of cardiac and cardiac-associated pathology in accordance with current recommendations. During the course of the study, the authors of the work do not interfere with the above-mentioned scope of the examination, which is carried out on patients in accordance with clinical guidelines. All patients included in the study will undergo ECG recording in standard lead I for 1 minute twice, followed by spectral analysis of the obtained data, which will be stored at the remote monitoring center of Sechenov University without being linked to the personal data of patients. A spectral analysis of the electrocardiogram will be performed using a continuous wavelet transform. The result of this study will be the identification of ECG parameters that will correlate with cardiac and cardiac-associated pathology
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 4000 (estimated)
- First submitted
- 2 Feb 2026
- Start date
- 1 Apr 2026
- Primary completion date
- 1 Mar 2028
- Lead sponsor
- I.M. Sechenov First Moscow State Medical University
- Diseases
- Chronic kidney disease, Heart failure, Coronary artery disease, Familial hypercholesterolaemia, High blood pressure
- NCT number
- NCT07396792
What you commit to
- Study type: Observational
- Planned participants: 4000
- From 1 Apr 2026 to the primary completion date, 1 Mar 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Insufficient examination data to verify or exclude cardiac or cardiac-associated pathology;
Other
- Poor quality of the ECG recording on a single-channel ECG monitor
- Patient's unwillingness to continue participating in the study for any reason.
Who the study is looking for
- The presence of written informed consent of the patient to participate in the study
- Availability of examination data allowing for the verification or exclusion of cardiac and cardiac-associated pathology
- Age 18 years old and older
- Non-inclusion criteria:
- Patients with an implanted permanent pacemaker;
- ECG changes that prevent spectral analysis;
- Conditions that may impair the quality of the ECG recording (Parkinson's disease, essential tremor, etc.);
- Conditions that make ECG recording in lead I impossible (congenital anomalies of the upper limbs, traumatic amputation of the upper limbs).
- Lack of written informed consent from the patient to participate in the study.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.